Tuesday, November 7, 2017
- 9:00AM-11:00AM
-
Abstract Number: 2229
The Effect of Intra-Articular Neurotoxin on Arthritis Pain and Substance P Expression in the Dorsal Root Ganglion: Results from Murine Arthritis Models
Pain – Basic and Clinical Aspects Poster- 9:00AM-11:00AM
-
Abstract Number: 2604
The Effect of Subcutaneous Belimumab on Corticosteroid Use in Patients with Systemic Lupus Erythematosus (SLE): A Phase 3, Randomized, Placebo-Controlled Study
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design- 9:00AM-11:00AM
-
Abstract Number: 2075
The Effect of Uric Acid Lowering Treatment on the Microbiome in Gout Patients
Metabolic and Crystal Arthropathies Poster II- 9:00AM-11:00AM
-
Abstract Number: 2245
The Effects of Structural Damage on Functional Disability in Psoriatic Arthritis
Patient Outcomes, Preferences, and Attitudes Poster III- 9:00AM-11:00AM
-
Abstract Number: 2598
The Effects of Tai Chi on Inflammatory Mediator Secretion in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design- 9:00AM-11:00AM
-
Abstract Number: 2371
The Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis Stratified By Baseline Body Mass Index
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1981
The Etiology of Fibromyalgia May be Related to Increased Muscle Pressure
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II- 9:00AM-11:00AM
-
Abstract Number: 2662
The EULAR Systemic Sclerosis Impact of Disease (ScleroID) Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis – Preliminary Results from the Ongoing Validation Study
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III- 9:00AM-11:00AM
-
Abstract Number: 2570
The Functional Consequence of Human (hu)TLR8 on Macrophage Immunometabolism and Renal Inflammation in Murine Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Animal Models Poster- 9:00AM-11:00AM
-
Abstract Number: 2547
the Ideal Target for Psoriatic Arthritis? Comparison of Remission and Low Disease Activity States in a Real Life Cohort
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2048
the Impact of Diagnostic Misregistration of Rheumatoid Arthritis on the Establishment of a Value Based Healthcare System
Measures and Measurement of Healthcare Quality Poster II- 9:00AM-11:00AM
-
Abstract Number: 2302
The Impact of JIA on Physician and Patient-Reported Outcomes over the First Five Years Following Diagnosis
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis- 9:00AM-11:00AM
-
Abstract Number: 2083
The Inflammation Induced By Four Types of Calcium Pyrophosphate Crystals Depends on Their Capacity to Stimulate NF-κb and MAPK Pathways
Metabolic and Crystal Arthropathies Poster II- 9:00AM-11:00AM
-
Abstract Number: 2341
The Interaction between Genetic Risk Factors and Age of Disease Onset in Juvenile Dermatomyositis